SCHEMBL6073396

SCHEMBL6073396

CCCN1C(=O)CSC1=O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.61
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
HSD17B10 Q99714 1/20 0.47
GSK3A P49840 2/20 0.47
GSK3B P49841 2/20 0.47
POLB P06746 2/20 0.45
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
PIM1 P11309 1/20 0.42
GFER P55789 1/20 0.42
TP53 P04637 1/20 0.41
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9068830 0.88 MAPT (0.58) MAPTALDH1A1SMN1; SMN2HSD17B10GSK3A
SCHEMBL5275664 0.86 MAPT (0.56) MAPTALDH1A1SMN1; SMN2HSD17B10GSK3A
SCHEMBL20176216 0.84 MAPT (0.54) MAPTALDH1A1SMN1; SMN2HSD17B10GSK3A
SCHEMBL181852 0.82
SCHEMBL3138532 0.79 GSK3A (0.56) MAPTALDH1A1HSD17B10GSK3AGSK3B
SCHEMBL11173506 0.78 MAPT (0.56) MAPTALDH1A1SMN1; SMN2HSD17B10GSK3A
SCHEMBL1693423 0.78 MAPT (0.56) MAPTALDH1A1SMN1; SMN2HSD17B10GSK3A
SCHEMBL1692808 0.78 MAPT (0.56) MAPTALDH1A1SMN1; SMN2HSD17B10GSK3A
SCHEMBL2360918 0.78 MAPT (0.56) MAPTALDH1A1SMN1; SMN2HSD17B10GSK3A
SCHEMBL2633830 0.78 ALDH1A1 (0.58) MAPTALDH1A1SMN1; SMN2HSD17B10GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2943584-B1 MACROPHAGE IDENTIFICATION AGENT, AND IDENTIFICATION METHOD, SORTING METHOD, EVALUATION METHOD, SCREENING METHOD AND KIT USING THE MACROPHAGE IDENTIFIER AGENT CANON KK (JP) 2019-08-14 EP disclosed
US-10041937-B2 Macrophage identification agent, and identification method, sorting method, evaluation method, screening method and kit using the macrophage identifier agent CANON KABUSHIKI KAISHA (JP) 2018-08-07 US disclosed
US-10041937-B2 Macrophage identification agent, and identification method, sorting method, evaluation method, screening method and kit using the macrophage identifier agent CANON KABUSHIKI KAISHA (JP) 2018-08-07 US disclosed
US-20160018389-A1 MACROPHAGE IDENTIFICATION AGENT, AND IDENTIFICATION METHOD, SORTING METHOD, EVALUATION METHOD, SCREENING METHOD AND KIT USING THE MACROPHAGE IDENTIFIER AGENT CANON KABUSHIKI KAISHA (JP) 2016-01-21 US disclosed
US-20160018389-A1 MACROPHAGE IDENTIFICATION AGENT, AND IDENTIFICATION METHOD, SORTING METHOD, EVALUATION METHOD, SCREENING METHOD AND KIT USING THE MACROPHAGE IDENTIFIER AGENT CANON KABUSHIKI KAISHA (JP) 2016-01-21 US disclosed
US-9115122-B2 Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) UNIVERSITY OF MARYLAND, BALTIMORE (US) 2015-08-25 US disclosed
WO-2014192972-A1 MACROPHAGE IDENTIFICATION AGENT, AND IDENTIFICATION METHOD, SORTING METHOD, EVALUATION METHOD, SCREENING METHOD AND KIT USING THE MACROPHAGE IDENTIFIER AGENT CANON KABUSHIKI KAISHA (JP) 2014-12-04 WO disclosed
US-20140179743-A1 NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-06-26 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
WO-2006013445-A2 THIAZOLIDINEDIONE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 MAPT 2536/4885ALDH1A1 364/4885SMN1; SMN2 4693/4885
US-10041937-B2 Macrophage identification agent, and identification method, sorting method, evaluation method, screening method and kit using the macrophage identifier agent CD68, MSR1, MYADM MAPT 4796/4885ALDH1A1 582/4885SMN1; SMN2 4336/4885
US-20140179743-A1 NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) MAPK1, MAP3K1, MAP3K20 MAPT 3850/4885ALDH1A1 1499/4885SMN1; SMN2 4591/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR MAPT 2469/4885ALDH1A1 340/4885SMN1; SMN2 4695/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR MAPT 2415/4885ALDH1A1 362/4885SMN1; SMN2 4709/4885
US-20160018389-A1 MACROPHAGE IDENTIFICATION AGENT, AND IDENTIFICATION METHOD, SORTING METHOD, EVALUATION METHOD, SCREENING METHOD AND KIT USING THE MACROPHAGE IDENTIFIER AGENT CD68, MSR1, MYADM MAPT 4796/4885ALDH1A1 582/4885SMN1; SMN2 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.